Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

HIV Medicine

Volumn 19, Issue 1, 2018, Pages e1-e42

  Bamford, A ^a   Turkova, A ^b   Lyall, H ^c   Foster, C ^c   Klein, N ^d   Bastiaans, D ^e   Burger, D ^e   Bernadi, S ^f   Butler, K ^g   Chiappini, E ^h   Clayden, P ⁱ   Della Negra, M ^j   Giacomet, V ^k   Giaquinto, C ^l   Gibb, D ^b   Galli, L ^m   Hainaut, M ⁿ   Koros, M ^o   Marques, L ^p   Nastouli, E ^q   Niehues, T ^r   Noguera Julian, A ^s   Rojo, P ^t   Rudin, C ^u   Scherpbier, H J ^v   Tudor Williams, G ^w   Welch, S B ^x   more..

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ 107 the Maltings   (United Kingdom)

^j INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^k UNIVERSITY OF MILAN   (Italy)

^l UNIVERSITY OF PADOVA   (Italy)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^o PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^p Centro Hospitalar e Universitário do Porto   (Portugal)

^q UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^r Helios Hospital Krefeld   (Germany)

^s UNIVERSITY OF BARCELONA   (Spain)

^t HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^u UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^v ACADEMIC MEDICAL CENTER   (Netherlands)

^w IMPERIAL COLLEGE LONDON   (United Kingdom)

^x BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

more..

Author keywords

antiretroviral therapy; child; HIV 1

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CARBAMAZEPINE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COTRIMOXAZOLE; DARUNAVIR; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; SULFONAMIDE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CHILD; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; INFECTION PREVENTION; MEDICATION COMPLIANCE; MIXED INFECTION; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; TRANSITION TO ADULT CARE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AIDS RELATED COMPLEX; COMPLICATION; EUROPE; FEMALE; INFANT; MALE; NEWBORN; PRESCHOOL CHILD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COINFECTION; EUROPE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE;

EID: 84922382127     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12217     Document Type: Article

References (226)

1. PENTA Steering Committe, Welch S, Sharland M et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591–613.
2. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med 2014; 15 (Suppl 1): 1–85.
3. European AIDS Clinical Society. EACS guidelines. 2013. Available at http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf (accessed June 2014).
4. Department of Health and Humas Services. Panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2014. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf (accessed June 2014).
5. Department of Health and Humas Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed June 2014).
6. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available at http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 (accessed June 2014).
7. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS 2013; 27: 1839–1846.
8. Nesheim S, Palumbo P, Sullivan K et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr 2003; 32: 192–195.
9. Dunn DT, Brandt CD, Krivine A et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9: F7–11.
10. Delamare C, Burgard M, Mayaux MJ et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. The French Pediatric HIV Infection Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 121–125.
11. Lee BE, Plitt SS, Jayaraman GC et al. Use of quantitative HIV RNA detection for early diagnosis of HIV infection in infants and acute HIV infections in Alberta, Canada. J Clin Microbiol 2012; 50: 502–505.
12. Burgard M, Blanche S, Jasseron C et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012; 160: 60–66. e61.
13. Bhowan K, Sherman GG. Performance of the first fourth-generation rapid human immunodeficiency virus test in children. Pediatr Infect Dis J 2013; 32: 486–488.
14. Swanson P, de Mendoza C, Joshi Y et al. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 2005; 43: 3860–3868.
15. Payne H, Mkhize N, Morris L et al. Routine Antibody tests have no place in determining HIV status after early ART: evidence from CHER. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
16. Judd A, Ferrand RA, Jungmann E et al. Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. HIV Med 2009; 10: 253–256.
17. British HIV Association, Children's HIV Association. ‘Don't foget the children’ Guidance for the HIV testing ofchildren with HIV-positive parents. 2009. Available at http://www.bhiva.org/documents/Guidelines/Dont%20Forget%20the%20Children/DFTC.pdf (accessed June 2014).
18. Delaugerre C, Chaix ML, Blanche S et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology 2009; 6: 85.
19. Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363–371.
20. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.
21. Menson EN, Mellado MJ, Bamford A et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012; 13: 333–336. e331–314.
22. Taylor GP, Clayden P, Dhar J et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13 (Suppl 2): 87–157.
23. Rabie H, Violari A, Duong T et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guerin immune reconstitution adenitis. Int J Tuberc Lung Dis 2011; 15: 1194–1200.
24. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. 2006. Available at http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf (accessed June 2014).
25. Chintu C, Bhat GJ, Walker AS et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364: 1865–1871.
26. Dunn D, Newell M, Ades T, Peckham C, Maria A. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group. BMJ 1994; 308: 437–440.
27. Thyagarajan B, Deshpande SS. Cotrimoxazole and neonatal kernicterus: a review. Drug Chem Toxicol 2014; 37: 121–129.
28. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access. 2006. Available at http://www.who.int/hiv/pub/guidelines/art/en/index.html (accessed June 2014).
29. Caldwell M, Oxtoby M, Simonds R, Rogers M. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43 (RR-12): 1–10.
30. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S et al. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014; 370: 41–53.
31. WHO. Co-trimoxazole prophylaxis for HIV-exposed and HIV-infects infants and children. 2009. Available at http://www.who.int/hiv/pub/paediatric/cotrimoxazole.pdf?ua=1 (accessed June 2014).
32. Manyando C, Njunju EM, D'Alessandro U, Van Geertruyden JP. Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS ONE 2013; 8: e56916.
33. Urschel S, Ramos J, Mellado M et al. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005; 19: 2103–2108.
34. Nachman S, Gona P, Dankner W et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115: e488–e494.
35. Siberry GK, Abzug MJ, Nachman S et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J 2013; 32 (Suppl 2): i–KK4.
36. Cotton MF, Violari A, Otwombe K et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 2013; 382: 1555–1563.
37. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233–2244.
38. Goetghebuer T, Haelterman E, Le Chenadec J et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23: 597–604.
39. Hainline C, Taliep R, Sorour G et al. Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. BMC Res Notes 2011; 4: 448.
40. Madhi SA, Adrian P, Cotton MF et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202: 355–361.
41. Laughton B, Cornell M, Grove D et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012; 26: 1685–1690.
42. Judd A, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996–2008: treatment response and duration of first-line regimens. AIDS 2011; 25: 2279–2287.
43. Chiappini E, Galli L, Tovo PA et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis 2009; 9: 140.
44. Goetghebuer T, Le Chenadec J, Haelterman E et al. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis 2012; 54: 878–881.
45. Palumbo PE, Raskino C, Fiscus S et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998; 279: 756–761.
46. Mofenson LM, Korelitz J, Meyer WA, 3rd et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997; 175: 1029–1038.
47. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 1605–1611.
48. Sturt AS, Halpern MS, Sullivan B, Maldonado YA. Timing of antiretroviral therapy initiation and its impact on disease progression in perinatal human immunodeficiency virus-1 infection. Pediatr Infect Dis J 2012; 31: 53–60.
49. HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20: 1289–1294.
50. HIV Paediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366: 1868–1874.
51. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283–2296.
52. Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197: 398–404.
53. Puthanakit T, Saphonn V, Ananworanich J et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 2012; 12: 933–941.
54. HIV Paediatric Prognostic Markers Collaborative Study Group, Dunn DT, Castro H et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010; 24: 1213–1217.
55. Cotugno N, Douagi I, Rossi P, Palma P. Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. Clin Dev Immunol 2012; 2012: 805151.
56. Picat MQ, Lewis J, Musiime V et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med 2013; 10: e1001542.
57. Lewis J, Walker AS, Castro H et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 2012; 205: 548–556.
58. Buzon MJ, Martin-Gayo E, Pereyra F et al. Long-term antiretroviral treatment initiated in primary HIV-1 infection affects the size, composition and decay kinetics of the reservoir of HIV-1 infected CD4 T cells. J Virol 2014; 88: 10056–10065.
59. Persaud D, Palumbo PE, Ziemniak C et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26: 1483–1490.
60. Avettand-Fenoel V, Blanche S, Le Chenadec J et al. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis 2012; 205: 1520–1528.
61. Lundgren JD, Babiker AG, Gordin FM, Borges AH, Neaton JD. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med 2013; 11: 148.
62. Franco RA, Saag MS. When to start antiretroviral therapy: as soon as possible. BMC Med 2013; 11: 147.
63. Schomaker M, Egger M, Ndirangu J et al. When to start antiretroviral therapy in children aged 2–5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med 2013; 10: e1001555.
64. Coovadia A, Abrams EJ, Stehlau R et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304: 1082–1090.
65. Palumbo P, Lindsey JC, Hughes MD et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510–1520.
66. McArthur MA, Kalu SU, Foulks AR et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J 2009; 28: 1127–1129.
67. Simon A, Warszawski J, Kariyawasam D et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011; 306: 70–78.
68. Violari A, Lindsey JC, Hughes MD et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380–2389.
69. Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev 2012; (7): CD004772.
70. PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11: 273–283.
71. Ruel TD, Kakuru A, Ikilezi G et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2014; 65: 535–541.
72. ARROW Trial team, Kekitiinwa A, Cook A et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381: 1391–1403.
73. Duong T, Judd A, Collins I et al. Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS 2014; 28: 2395–2405.
74. Bertz R, Tafoya E, Chapel S et al. Population pharmacokinetics of efavirenz in pediatric patients to inform dosing in children ≥ 3 months of age. 14th International Workshop on Clinical Pharmacology of HIV Therapy. The Netherlands, 2013.
75. Food and Drug Administration. Sustiva prescribing information. 2013. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020972s046,021360s035lbl.pdf (accessed June 2014).
76. Moore CB, Capparelli E, Samson P et al., eds. CYP2B6 Polymorphisms Challenge Generalized FDA Efavirenz Dosing Guidelines in Children < 3 Yrs. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
77. Pillay P, Ford N, Shubber Z, Ferrand RA. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS ONE 2013; 8: e68995.
78. Lowenthal ED, Ellenberg JH, Machine E et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA 2013; 309: 1803–1809.
79. Kekitiinwa A, Spyer M, Katuramu R et al. Virologic Response To Efavirenz vs Nevirapine-Containing ART in the ARROW Trial. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
80. Shubber Z, Calmy A, Andrieux-Meyer I et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27: 1403–1412.
81. Lyall H. Final results of koncert: a randomized noninferiority trial of QD vs BD LPV/r dosing in children. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
82. Food and Drug Administration. Lexiva prescribing information. 2012. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021548s031,022116s015lbl.pdf (accessed June 2014).
83. Green H, Gibb DM, Walker AS et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21: 947–955.
84. Harrison L, Gibb D, Fiscus S et al. HIV-1 resistance after randomized virologic switch at 1000 or 30,000 c/ml in children. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
85. Gibb DM, Walker AS, Kaye S et al. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antivir Ther 2002; 7: 293–303.
86. Musiime V, Kendall L, Bakeera-Kitaka S et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15: 1115–1124.
87. Paediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010; 15: 297–305.
88. LePrevost M, Green H, Flynn J et al. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25: 533–537.
89. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391–1399.
90. Viani RM, Alvero C, Fenton T et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV+ children. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
91. Viani RM, Alvero C, Fenton T et al. Safety and efficacy of dolutegravir in HIV treatment-experienced adolescents: 48-week results. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
92. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav 2013; 17: 86–93.
93. Letourneau EJ, Ellis DA, Naar-King S et al. Multisystemic therapy for poorly adherent youth with HIV: results from a pilot randomized controlled trial. AIDS Care 2013; 25: 507–514.
94. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev 2011; (12): CD009513.
95. Simoni JM, Montgomery A, Martin E et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119: e1371–e1383.
96. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep 2009; 6: 194–200.
97. Nachega JB, Parienti JJ, Uthman OA et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58: 1297–1307.
98. Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. Curr Opin Obstet Gynecol 2011; 23: 321–327.
99. Butler AM, Williams PL, Howland LC et al. Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics 2009; 123: 935–943.
100. Saunders C. Disclosing HIV status to HIV positive children before adolescence. Br J Nurs 2012; 21: 663–669.
101. Burger DM. The role of therapeutic drug monitoring in pediatric HIV/AIDS. Ther Drug Monit 2010; 32: 269–272.
102. Rakhmanina NY, van den Anker JN, Soldin SJ et al. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit 2010; 32: 273–281.
103. Alam N, Cortina-Borja M, Goetghebuer T et al. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr 2012; 59: 314–324.
104. Bavinger C, Bendavid E, Niehaus K et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS ONE 2013; 8: e59551.
105. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012; 13: 453–468.
106. Martinez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 2009; 22: 28–34.
107. Charakida M, Loukogeorgakis SP, Okorie MI et al. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir Ther 2009; 14: 1075–1079.
108. Sainz T, Alvarez-Fuente M, Navarro ML et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study. J Acquir Immune Defic Syndr 2014; 65: 42–49.
109. Di Biagio A, Rosso R, Maggi P et al. Inflammation markers correlate with common carotid intima-media thickness in patients perinatally infected with human immunodeficiency virus 1. J Ultrasound Med 2013; 32: 763–768.
110. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7: 733–738.
111. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc 2013; 16: 18600.
112. Arpadi S, Shiau S, Strehlau R et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child 2013; 98: 258–264.
113. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr 2011; 57: 404–412.
114. Souza SJ, Luzia LA, Santos SS, Rondo PH. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras 2013; 59: 186–198.
115. Orkin C, DeJesus E, Khanlou H et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 2013; 14: 49–59.
116. Lu CL, Lin YH, Wong WW et al. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. J Microbiol Immunol Infect 2011; 44: 258–264.
117. European Medicines Agency. Reyataz: product information. 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000494/WC500056380.pdf (accessed June 2014).
118. Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 1993–2004.
119. Puthanakit T, Siberry GK. Bone health in children and adolescents with perinatal HIV infection. J Int AIDS Soc 2013; 16: 18575.
120. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152: 582–584.
121. Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118: e711–e718.
122. WHO. Use of tenofovir in HIV-infected children and adolescents: a public health perspective. 2012. Available at http://apps.who.int/iris/bitstream/10665/70944/1/9789241503822_eng.pdf?ua=1 (accessed June 2014).
123. Sirisanthana V. 48-week safety of tenofovir when administered according to weight-band dosing in HIV+ children > 15 kg as part of a once-daily HAART regimen. Conference on Retroviruses and Opportunistic Infections. Atlanta, USA, 2013.
124. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV-1 infection. J Int AIDS Soc 2013; 16: 18596.
125. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
126. Vispo E, Cevik M, Rockstroh JK et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis 2013; 56: 1117–1122.
127. Scourfield A, Waters L, Holmes P et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22: 324–328.
128. Kovari H, Ledergerber B, Peter U et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49: 626–635.
129. Giacomet V, Vigano A, Penagini F et al. Splenomegaly and variceal bleeding in a ten-year-old HIV-infected girl with noncirrhotic portal hypertension. Pediatr Infect Dis J 2012; 31: 1059–1060.
130. Scherpbier HJ. Antiretroviral therapy associated liver disease in 4 HIV-1 infected adolescent girls. EASL Monothematic Conference: HIV and the liver. London, UK, 2012.
131. European Medicines Agency. Combivir: product information. 2013. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000190/WC500032326.pdf (accessed June 2014).
132. Giaquinto C, Keet L, Fortuny C et al. Safety and efficacy of maraviroc in CCR5-tropic HIV-1-infected children aged 2 to < 18 years. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia, 2013.
133. Abad C, Fortuny C, Almendros P et al. Progressive liver disease in patients with vertically acquired HIV/HCV co-infection in Spain. 5th International Workshop on HIV Paediatrics. Kuala Lumpur, Malaysia, 2013.
134. Chamie G, Bonacini M, Bangsberg DR et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis 2007; 44: 577–583.
135. George SL, Gebhardt J, Klinzman D et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002; 31: 154–162.
136. Farmand S, Wirth S, Loffler H et al. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr 2012; 171: 253–258.
137. Bortolotti F, Verucchi G, Camma C et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900–1907.
138. Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2013. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (accessed June 2014).
139. Wilkins E, Nelson M, Agarwal K et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14 (Suppl 4): 1–71.
140. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174–S184.
141. Sokal EM, Paganelli M, Wirth S et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013; 59: 814–829.
142. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12–22.
143. Claret-Teruel G, Noguera-Julian A, Esteva C et al. Impact of human immunodeficiency virus coinfection on the progression of mother-to-child transmitted hepatitis C virus infection. Pediatr Infect Dis J 2011; 30: 801–804.
144. Mohan N, Gonzalez-Peralta RP, Fujisawa T et al. Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr 2010; 50: 123–131.
145. Mack CL, Gonzalez-Peralta RP, Gupta N et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838–855.
146. Sokal EM, Bourgois A, Stephenne X et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827–831.
147. Wirth S, Ribes-Koninckx C, Calzado MA et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501–507.
148. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012; 18: 99–104.
149. Hesseling AC, Cotton MF, Jennings T et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 2009; 48: 108–114.
150. Marais BJ, Graham SM, Cotton MF, Beyers N. Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 2007; 196 (Suppl 1): S76–S85.
151. Jensen J, Alvaro-Meca A, Micheloud D, Diaz A, Resino S. Reduction in mycobacterial disease among HIV-infected children in the highly active antiretroviral therapy era (1997–2008). Pediatr Infect Dis J 2012; 31: 278–283.
152. Li N, Manji KP, Spiegelman D et al. Incident tuberculosis and risk factors among HIV-infected children in Tanzania. AIDS 2013; 27: 1273–1281.
153. Edmonds A, Lusiama J, Napravnik S et al. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009; 38: 1612–1621.
154. Martinson NA, Moultrie H, van Niekerk R et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009; 13: 862–867.
155. Schaaf HS, Cotton MF, Boon GP, Jeena PM. Isoniazid preventive therapy in HIV-infected and -uninfected children (0–14 years). S Afr Med J 2013; 103: 714–715.
156. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; (1): CD000171.
157. Spyridis NP, Spyridis PG, Gelesme A et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715–722.
158. Bright-Thomas R, Nandwani S, Smith J, Morris JA, Ormerod LP. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child 2010; 95: 600–602.
159. Sester M, Sotgiu G, Lange C et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100–111.
160. Chiappini E, Bonsignori F, Accetta G et al. Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a literature review. Int J Immunopathol Pharmacol 2012; 25: 335–343.
161. Bunsow E, Ruiz-Serrano MJ, Lopez Roa P et al. Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens. J Infect 2014; 68: 338–343.
162. Abdool Karim SS, Naidoo K, Grobler A et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492–1501.
163. Blanc FX, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471–1481.
164. Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482–1491.
165. Yotebieng M, Van Rie A, Moultrie H et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010; 24: 1341–1349.
166. Frohoff C, Moodley M, Fairlie L et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS ONE 2011; 6: e17273.
167. Ren Y, Nuttall JJ, Egbers C et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47: 566–569.
168. Oudijk JM, McIlleron H, Mulenga V et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS 2012; 26: 1523–1528.
169. Grinsztejn B, De Castro N, Arnold V et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014; 14: 459–467.
170. International Union Against Tuberculosis and Lung Disease, WHO. Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: recommendations for a public health approach. 2010. Available at http://www.theunion.org/what-we-do/publications/english/pub_tbhivchildfinaldoc_webversion2.pdf (accessed June 2014).
171. Gkentzi D, Tebruegge M, Tudor-Williams G et al. Incidence, spectrum and outcome of immune reconstitution syndrome in HIV-infected children following initiation of antiretroviral therapy. Pediatr Infect Dis J 2014; 33: 953–958.
172. Shah I. Immune Reconstitution Syndrome in HIV-1 infected children – a study from India. Indian J Pediatr 2011; 78: 540–543.
173. Walters E, Cotton MF, Rabie H et al. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008; 8: 1.
174. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007; 11: 417–423.
175. Puthanakit T, Oberdorfer P, Akarathum N et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006; 25: 53–58.
176. Laureillard D, Marcy O, Madec Y et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013; 27: 2577–2586.
177. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516–523.
178. WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006. Available at http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf?ua=1 (accessed June 2014).
179. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf?ua=1 (accessed June 2014).
180. Makadzange AT, Ndhlovu CE, Takarinda K et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50: 1532–1538.
181. Wamalwa DC, Lehman DA, Benki-Nugent S et al. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 62: 267–274.
182. Ruel TD, Kamya MR, Li P et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011; 56: 44–50.
183. Briz V, Garcia D, Mendez-Lagares G et al. High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission. Pediatr Infect Dis J 2012; 31: 1048–1052.
184. Frange P, Briand N, Veber F et al. CCR5 antagonists: a therapeutic option in HIV-1 perinatally infected children experiencing virologic failure? AIDS 2012; 26: 1673–1677.
185. Lee KJ, Shingadia D, Pillay D et al. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean? Antivir Ther 2007; 12: 949–956.
186. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377: 1580–1587.
187. de Mulder M, Yebra G, Navas A et al. High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain. PLoS ONE 2012; 7: e52155.
188. Collaborative HIV paediatric Study. CHIPS annual report 2012/2013. 2013. Available at http://www.chipscohort.ac.uk/summary_data.asp. (accessed June 2014).
189. Briz V, Leon-Leal JA, Palladino C et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 2012; 31: 273–277.
190. Palladino C, Briz V, Gonzalez-Tome MI et al. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials. AIDS Res Hum Retroviruses 2010; 26: 301–305.
191. Tudor-Williams G, Cahn P, Chokephaibulkit K et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Med 2014; 15: 513–524.
192. Briz V, Palladino C, Navarro M et al. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. HIV Med 2011; 12: 442–446.
193. Ruxrungtham K, Pedro RJ, Latiff GH et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9: 883–896.
194. Food and Drug Administration. Complera prescribing information. 2013. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202123s003lbl.pdf (accessed June 2014).
195. European Medicines Agency. Eviplera: product information. 2014. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312/WC500118802.pdf (accessed June 2014).
196. Xiang N, James M, Walters S, Bamford A, Foster C. Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir. HIV Med 2014; 15: 635–636.
197. Kuhn L, Coovadia A, Strehlau R et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012; 12: 521–530.
198. Coovadia A, Abrams E, Strehlau R et al. Virologic efficacy of efavirenz maintenance therapy in nevirapine prophylaxis-exposed children. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
199. Paton N, Stohr W, Arenas-Pinto A, Dunn D, Group PT. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management. Conference on Retroviruses and Opportunistic Infections. Boston, USA, 2014.
200. Neth O, Falcon-Neyra L, Ruiz-Valderas R et al. Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy. Pediatr Infect Dis J 2011; 30: 917.
201. Bunupuradah T, Kosalaraksa P, Puthanakit T et al. Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. AIDS 2011; 25: 315–323.
202. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21: 6–13.
203. Paediatric European Network for Treatment of A. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010; 24: 231–241.
204. Bunupuradah T, Duong T, Compagnucci A et al. Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. AIDS 2013; 27: 579–589.
205. Klein N, Sefe D, Mosconi I et al. The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS ONE 2013; 8: e76582.
206. Wamalwa D, Benki-Nugent S, Langat A et al. Treatment interruption in infants following 24 months of empiric ART: Kenya. Conference on Retroviruses and Opportunistic Infections. Seattle, USA, 2012.
207. Siberry GK, Patel K, Van Dyke RB et al. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr 2011; 57: 223–229.
208. Fox Z, Phillips A, Cohen C et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008; 22: 2279–2289.
209. Cressey TR, Green H, Khoo S et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008; 46: 1601–1608.
210. SPARTAC Trial Investigators, Fidler S, Porter K et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368: 207–217.
211. Lodi S, Meyer L, Kelleher AD et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172: 1252–1255.
212. Saez-Cirion A, Bacchus C, Hocqueloux L et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211.
213. Ananworanich J, Puthanakit T, Suntarattiwong P et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28: 1015–1020.
214. Persaud D, Gay H, Ziemniak C et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369: 1828–1835.
215. Persaud D, Deveikis A, Gay H et al. Very early combination antiretroviral therapy in perinatal HIV infection: two case studies. Conference on Retrovirus and Opportunistic Infections. Boston, USA, 2014.
216. National Institiue of Allergy and Infectious Diseases. ‘Mississippi Baby’ now has detectable HIV, researchers find. 2014. Available at http://www.niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx (accessed June 2014).
217. Department of Health. Transition: getting it right for young people. 2006. Available at http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4132149.pdf (accessed June 2014).
218. Wiener LS, Kohrt BA, Battles HB, Pao M. The HIV experience: youth identified barriers for transitioning from pediatric to adult care. J Pediatr Psychol 2011; 36: 141–154.
219. Bundock H, Fidler S, Clarke S et al. Crossing the divide: transition care services for young people with HIV-their views. AIDS Patient Care STDS 2011; 25: 465–473.
220. Vijayan T, Benin AL, Wagner K, Romano S, Andiman WA. We never thought this would happen: transitioning care of adolescents with perinatally acquired HIV infection from pediatrics to internal medicine. AIDS Care 2009; 21: 1222–1229.
221. Khan M, Song X, Williams K et al. Evaluating adherence to medication in children and adolescents with HIV. Arch Dis Child 2009; 94: 970–973.
222. Mellins CA, Brackis-Cott E, Leu CS et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry 2009; 50: 1131–1138.
223. Domek GJ. Facing adolescence and adulthood: the importance of mental health care in the global pediatric AIDS epidemic. J Dev Behav Pediatr 2009; 30: 147–150.
224. Mellins CA, Elkington KS, Leu CS et al. Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth. AIDS Care 2012; 24: 953–962.
225. Malee KM, Tassiopoulos K, Huo Y et al. Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care 2011; 23: 1533–1544.
226. Gadow KD, Chernoff M, Williams PL et al. Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. J Dev Behav Pediatr 2010; 31: 116–128.